PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations

Andreas H. Scheel*, Sascha Ansén, Anne M. Schultheis, Matthias Scheffler, Rieke N. Fischer, Sebastian Michels, Martin Hellmich, Julie George, Thomas Zander, Michael Brockmann, Erich Stoelben, Harry Groen, Wim Timens, Sven Perner, Michael von Bergwelt-Baildon, Reinhard Büttner, Jürgen Wolf

*Corresponding author for this work
55 Citations (Scopus)


Inhibition of the PD-1/PD-L1 pathway may induce anticancer immune responses in non-small cell lung cancer (NSCLC). Two PD-L1 immunohistochemistry (IHC) assays have been approved as companion diagnostic tests for therapeutic anti-PD-1 antibodies. However, many aspects of PD-L1 prevalence and association with genetically defined subtypes have not been addressed systematically. Here, we analyzed PD-L1 expression in 436 genetically annotated NSCLC specimens enriched for early stages using PD-L1 antibody 5H1. Expression of PD-L1 was detected in the tumor cells (TC) (34% of cases) and in associated immune cells (IC) (49%) across all stages of NSCLC, either alone or in combination. PD-L1 IHC-positive TC, but not IC showed significantly higher PD-L1 RNA expression levels. Expression in TC was associated with TP53, KRAS and STK11 mutational status in adenocarcinomas (AD) and with NFE2L2 mutations in squamous cell carcinomas (SQ). No correlations with histological subtype, clinical characteristics and overall survival were found. The presence of PD-L1-positive IC was significantly associated with patients' smoking status in AD. The findings are in agreement with the emerging concept that tumors with high mutational burden are more likely to benefit from immunotherapy, since TP53 and KRAS mutations are linked to smoking, increased numbers of somatic mutations and expression of neoantigens. Current clinical studies focus on stage IIIB and IV NSCLC; however, PD-L1 expression occurs in earlier stages and might be a predictive biomarker in clinical trials testing (neo-) adjuvant strategies.

Original languageEnglish
Article numbere1131379
Issue number5
Publication statusPublished - 03.05.2016


Dive into the research topics of 'PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations'. Together they form a unique fingerprint.

Cite this